Donald Edward White
#177,654
Most Influential Person Now
Donald Edward White's AcademicInfluence.com Rankings
Donald Edward Whitephilosophy Degrees
Philosophy
#10970
World Rank
#15064
Historical Rank
Logic
#7800
World Rank
#9681
Historical Rank
Donald Edward Whitebiology Degrees
Biology
#14775
World Rank
#18621
Historical Rank
Immunology
#1018
World Rank
#1043
Historical Rank
Download Badge
Philosophy Biology
Donald Edward White's Degrees
- PhD Immunology Stanford University
- Doctorate Medicine University of California, San Francisco
Why Is Donald Edward White Influential?
(Suggest an Edit or Addition)Donald Edward White's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002) (2901)
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1998) (1897)
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) (1640)
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy (2011) (1551)
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. (2009) (1401)
- Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. (2008) (1283)
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. (1994) (1118)
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (2006) (1088)
- Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients (1989) (995)
- Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. (1994) (983)
- Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. (2003) (784)
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007) (679)
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007) (612)
- Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
- Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma (2005) (500)
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma (2012) (462)
- Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. (2004) (449)
- Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. (1998) (410)
- A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma (2002) (368)
- Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. (1989) (361)
- Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. (1996) (355)
- Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. (1998) (334)
- Patterns of recurrence in patients with high-grade soft-tissue sarcomas. (1985) (326)
- Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. (2001) (322)
- CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma (2010) (289)
- Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. (1999) (284)
- High‐grade soft tissue sarcomas of the extremities (1986) (262)
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. (2016) (255)
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines (2008) (226)
- Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
- Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. (2013) (192)
- Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. (1991) (192)
- Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer (1998) (190)
- Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities. (1985) (174)
- Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1 (2007) (174)
- Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. (2017) (172)
- Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial (2014) (170)
- Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. (2006) (169)
- Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. (2017) (166)
- Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. (1987) (165)
- Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. (1987) (164)
- In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. (1994) (162)
- Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. (1994) (162)
- Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy (2010) (161)
- Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. (2001) (160)
- Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice (2001) (138)
- Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens (2003) (118)
- Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. (2003) (114)
- Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. (1999) (108)
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response (1999) (108)
- Cardiopulmonary toxicity of treatment with high dose interleukin‐2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma (1994) (106)
- Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL (2010) (104)
- Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. (2003) (99)
- Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. (1995) (92)
- Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases (2002) (92)
- Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone (1995) (91)
- Multifaceted Roles of Integrins in Breast Cancer Metastasis (2007) (81)
- The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. (1992) (77)
- The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma (1995) (73)
- Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth (2005) (73)
- Management and Outcome of Patients With Sporadic Gastrinoma Arising in the Duodenum (2003) (72)
- Thyroid dysfunction associated with immunotherapy for patients with cancer (1991) (70)
- Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. (1996) (70)
- Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner. (2013) (68)
- The Development of Gene Therapy for the Treatment of Cancer (1993) (68)
- HLA Associations in the Antitumor Response Against Malignant Melanoma (1995) (63)
- Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. (1989) (62)
- Extremity soft tissue sarcomas: Analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher‐grade sarcomas (1989) (61)
- Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. (1994) (59)
- A Prospective Randomized Trial Evaluating Colloid Versus Crystalloid Resuscitation in the Treatment of the Vascular Leak Syndrome Associated with Interleukin‐2 Therapy (1994) (57)
- Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen (2004) (57)
- A Prospective Analysis of Positron Emission Tomography and Conventional Imaging for Detection of Stage IV Metastatic Melanoma in Patients Undergoing Metastasectomy (2004) (52)
- Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. (1993) (50)
- HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. (1992) (48)
- Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma (2006) (47)
- The hematologic toxicity of interleukin‐2 in patients with metastatic melanoma and renal cell carcinoma (1995) (47)
- A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma (2004) (46)
- Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. (1998) (45)
- Addressing the Role of Cell Adhesion in Tumor Cell Dormancy (2006) (44)
- Functional and psychosocial effects of multimodality limb-sparing therapy in patients with soft tissue sarcomas. (1989) (40)
- Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA‐Cw*0702‐associated epitope MAGE‐A12:170–178 (2003) (39)
- Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. (1986) (37)
- Determinants of survival in patients with unresectable colorectal liver metastases (1989) (37)
- Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines (2006) (34)
- Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. (1992) (32)
- Water-soluble vitamins in cancer patients on parenteral nutrition: a prospective study. (1987) (32)
- Calcium and Phosphorus Metabolism During Total Parenteral Nutrition (1983) (31)
- Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases (2018) (30)
- Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy (2009) (28)
- Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients (2017) (26)
- Toxicity Studies of Adjuvant Intravenous Versus Intraperitoneal 5‐FU in Patients with Advanced Primary Colon or Rectal Cancer (1986) (23)
- Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. (2010) (23)
- High‐grade retroperitoneal sarcomas: Role of an aggressive palliative approach (1993) (22)
- A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreas. (1992) (21)
- Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma (2021) (20)
- Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration (2014) (19)
- A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. (1997) (18)
- Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation (2014) (17)
- Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. (1993) (16)
- Combination therapy with interferon-γ and interleukin-2 for the treatment of metastatic melanoma (1996) (15)
- Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? (1999) (14)
- Acute and long term effects on limb function of combined modality therapy in patients treated with limb sparing surgery for soft tissue sarcoma of the extremity (1990) (14)
- Assessment of Ovarian Function After Preparative Chemotherapy and Total Body Radiation for Adoptive Cell Therapy (2011) (13)
- Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. (2010) (11)
- Study on Adoptive Immunotherapy Using Gene-Modified TCells for Ovarian Cancer (2006) (9)
- Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. (1996) (8)
- Decreased Tolerance to Interleukin-2 With Repeated Courses of Therapy in Patients With Metastatic Melanoma or Renal Cell Cancer (2000) (8)
- Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma (2012) (8)
- Introduction of Konrad B. Krauskopf for the V. M. Goldschmidt Medal 1982 (1983) (2)
- NMDA Receptor-PSD-95 Protein Interactions Treatment of Ischemic Brain Damage by Perturbing (2006) (2)
- Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma (2003) (2)
- Changes in tumor tissue organization in collagen-I sensitize cells to ionizing radiation in an ex vivo model of solid mammary tumor growth and local invasion (2011) (1)
- Treatment of metastatic uveal melanoma with adoptive transfer of tumor infiltrating lymphocytes: a single-center phase 2 study (2017) (0)
- Award Number: W81XWH-07-1-0349 TITLE: In Vivo Analysis of Alternative Modes of Breast Cancer Cell Invasion (2008) (0)
- A study of the relationship of various strength and anthropometric measures as related to selected trunk and leg strength criteria (1955) (0)
- Clinical Cancer esearch cer Therapy : Clinical cessful Treatment of Melanoma Brain R astases with Adoptive Cell Therapy (2010) (0)
- In Vivo Analysis of Alternative Modes of Breast Cancer Cell Invasion (2008) (0)
- Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
- Randomized S tudy o f H igh-Dose a nd L ow-Dose I nterleukin-2 in P atients W ith M etastatic R enal C ancer (2003) (0)
- Routine imaging to detect recurrences in high-risk melanoma patients. (2011) (0)
- for Combination Metastatic Colorectal Cancer Using 5Fluorouracil, Leucovorin and Interleukin-2 (1993) (0)
- The role of β-integrin signaling in mammary gland tumourigenesis (2004) (0)
- VivoPartial Reduction in Regulatory T Cells In Metastatic Melanoma Induces a Selective Immunotoxin, LMB-2, to Patients with Administration of a CD25-Directed (2007) (0)
- The establishment of two novel bovine cell lines by transfection with the putative transforming region of bovine adenovirus type 3 (1996) (0)
- Locally recurrent disease following combined modality treatment of high-grade soft tissue sarcomas (1984) (0)
- Factors A ssociated W ith R esponse t o H igh-Dose Interleukin-2 i n P atients W ith M etastatic M elanoma (2001) (0)
- a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
- astases with Adoptive Cell Therapy (2010) (0)
- The Role of the Integrin-Linked Kinase (ILK) in Mammary Gland Tumorigenesis and Metastasis (2001) (0)
- IN VITRO PREDICTORS OF CLINICAL RESPONSE IN MELANOMA PATIENTS RECEIVING TUMOR INFILTRATING LYMPHOCYTE (TIL) IMMUNOTHERAPY (1993) (0)
This paper list is powered by the following services:
